Continuation of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Individuals: A Systematic Review
Authors' conclusion
Current data on discontinuation of GAHT show that the rates of GAHT discontinuation appear to be low and the reasons include both external pressures and internal change of gender identity. A better understanding of the internal and external pressures that impact the decision to continue GAHT is needed in future studies.
Study context
- Population
- Transgender and gender-diverse individuals using gender-affirming hormone therapy (GAHT)6 studies
- Outcome
- Continuation and discontinuation rates of GAHT and factors leading to discontinuation
Methodological detailsPubMed search 2009 to April 01, 2024, screening by 2 authors independently, 6 included studies published between 2021 and 2024
- PubMed search 2009 to April 01, 2024
- Screening by 2 authors independently
- 6 included studies published between 2021 and 2024
Pooled result
As reported in the abstract
GAHT discontinuation rates
Studies reporting GAHT discontinuation rates under 10%
5 studies
Discontinuation/lost to follow-up rate in 1 study
30.8%
Further pooled results
Reasons for GAHT discontinuation
- Studies describing reasons for discontinuation
- 2 studies
- One study: discontinuation primarily from external factors; the other: due to change in gender identity
Original publication
Continuation of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Individuals: A Systematic Review. Endocr Pract. Published 19 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →